Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

about

Real world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

P2860

Q54976753-22EB9FF7-9D28-47C9-B5DB-A741C3362219

P2860

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

Item

http://www.wikidata.org/entity/Q50054062

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Toxicities and outcomes of 616 ...... States: a real-world analysis.

@en

Toxicities and outcomes of 616 ...... States: a real-world analysis.

@nl

type

Item

label

Toxicities and outcomes of 616 ...... States: a real-world analysis.

@en

Toxicities and outcomes of 616 ...... States: a real-world analysis.

@nl

prefLabel

Toxicities and outcomes of 616 ...... States: a real-world analysis.

@en

Toxicities and outcomes of 616 ...... States: a real-world analysis.

@nl

P1476

Toxicities and outcomes of 616 ...... States: a real-world analysis.

@en

P2093

Alan Skarbnik

http://www.w3.org/2001/XMLSchema#string

Allison Winter

http://www.w3.org/2001/XMLSchema#string

Andre Goy

http://www.w3.org/2001/XMLSchema#string

Anthony R Mato

http://www.w3.org/2001/XMLSchema#string

Brian Hill

http://www.w3.org/2001/XMLSchema#string

Bruce D Cheson

http://www.w3.org/2001/XMLSchema#string

Chadhi Nabhan

http://www.w3.org/2001/XMLSchema#string

Chaitra S Ujjani

http://www.w3.org/2001/XMLSchema#string

Christina Howlett

http://www.w3.org/2001/XMLSchema#string

Clive Zent

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

Survival probabilities (the Kaplan-Meier method).

Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.

P304

874-879

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2017.182907

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29419429

http://www.w3.org/2001/XMLSchema#string

P932

5927982

http://www.w3.org/2001/XMLSchema#string

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

about

P2860

P2860

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932